San Francisco biotechs iZumi and Pierian recently merged to yield iPierian, following a trend of consolidating biotechs in the Boston area. The company will focus its efforts on the industrialization of induced pluripotent stem cells with the intent to create new therapy options through cellular reprogramming and induced differentiation. The company will continue iZumi’s focus on neurodegeneration, including a major focus on ALS. The San Francisco Business Journal reports further that the new company is receiving more than $10 million in venture capital based on the success of the two VC-based firms as individual entities.
Click here to read more.Share this: